Topical Tranexamic Acid is Equivalent to Targeted Preoperative Autologous Blood Donation in Total Hip Arthroplasty

2017 ◽  
Vol 32 (4) ◽  
pp. 1176-1179 ◽  
Author(s):  
Maximilian F. Kasparek ◽  
Martin Faschingbauer ◽  
Wenzel Waldstein ◽  
Cosima S. Boettner ◽  
Friedrich Boettner
2003 ◽  
Vol 30 (5) ◽  
pp. 210-213 ◽  
Author(s):  
M. Möllmann ◽  
M.M. von dem Berge ◽  
S. Gurlit ◽  
F.T. Fard ◽  
W. Sibrowski

2005 ◽  
Vol 33 (2) ◽  
pp. 91-97 ◽  
Author(s):  
Manuel Vargas-Pabon ◽  
Ana Diaz-Trapiella ◽  
Miguel Jimenez Hurtado ◽  
Nicolas Diaz Varela ◽  
Jose Luis Cerra Sabio

2021 ◽  
Author(s):  
Jing Yao Jin ◽  
Qing Song Li ◽  
Taek Rim Yoon ◽  
Sheng Yu Jin ◽  
Min Gwang Kim ◽  
...  

Abstract Introduction: This study was designed to compare the clinical results of additional administration of topical tranexamic acid (TXA) with intravenous TXA (IV-TXA) and to determine its effect in patients undergoing primary total hip arthroplasty (THA) without drainage using propensity score matching analysis.Methods: A total of 248 patients (248 hips) underwent primary THA from March 2016 to June 2018. Patients who received topical TXA and IV-TXA were included in the combined group (46 patients), and patients who received IV-TXA were included in the IV only group (202 patients). After propensity score matching, both groups consisted of 44 patients (88 patients in total). We compared the results of total blood loss (TBL), haemoglobin (Hb) level, Hb drop, and the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE). Results: In the combined group, the TBL was 280.4 ± 64.2 mL, which was significantly lower than that in the IV only group (335.3 ± 75.3 mL; p < 0.001). From the preoperative period to 1-week postoperatively, Hb levels were not significantly different between the two groups. There was significantly more Hb drop in the IV only Group from immediate postoperative to postoperative day 3 (POD 3). In both groups, no patient presented with postoperative symptomatic DVT or PE. Conclusion: In patients undergoing primary THA without drainage, combined use of IV-TXA and topical TXA can significantly decrease blood loss without influencing postoperative complications.


2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Walter Anazonwu ◽  
John Tuttle ◽  
Lee Rubin

Tranexamic acid (TXA) is an antifibrinolytic agent that can effectively be utilized for the reduction of blood loss when administered via intravenous or intraarticular injection following total joint arthroplasty. Despite data published to date, it remains unclear as to which specific patient groups undergoing primary total hip arthroplasty (THA) would benefit most regarding transfusion reduction from TXA administration. Using a retrospective cohort study model involving 123 THA patients who received topical TXA compared against 111 THA controls who did not receive TXA, we assessed data within the following subgroups: age, gender, BMI, preoperative hemoglobin, and surgical approach. Critical analysis of these subgroups revealed that the most reliable and consistent response to TXA was found in patients who were female and over 65 years old. Continued study of TXA administration in THA is essential to help reduce blood losses, minimize blood product transfusion, and improve outcomes following THA.


2019 ◽  
Vol 16 (S2) ◽  
pp. 285-292
Author(s):  
Elina Huerfano ◽  
Manuel Huerfano ◽  
Kate Shanaghan ◽  
Maureen Barlow ◽  
Stavros Memtsoudis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document